7.7.2. first-line systemic therapy metastatic disease. general, patients untreated metastatic uc divided two broad categories: eligible combination therapies ineligible combination therapies. distinction two groups currently based eligibility criteria pivotal trial ev-302/keynote 39a likely undergo changes near future based results real-world evidence investigations. major criteria include ecog performance status 0-2, gfr â‰¥ 30 ml/min adequate organ functions based eligibility treatment enfortumab vedotin pembrolizumab. regards platinum-based chemotherapy definitions distinguish patients fit cisplatin, fit carboplatin und unfit platinum-based therapy remains valid outlined summarised table 7.2.